These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34291599)

  • 1. Type O blood group associates with higher anti-JC polyomavirus antibody levels.
    Frenken P; Hartung HP; Olsson T; Adams O; Warnke C
    Brain Behav; 2021 Aug; 11(8):e2298. PubMed ID: 34291599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
    Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
    Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
    Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.
    Diotti RA; Mancini N; Clementi N; Sautto G; Moreno GJ; Criscuolo E; Cappelletti F; Man P; Forest E; Remy L; Giannecchini S; Clementi M; Burioni R
    Antiviral Res; 2014 Aug; 108():94-103. PubMed ID: 24909571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of JC polyomavirus-encoded microRNAs in progressive multifocal leukoencephalopathy tissues and its repressive role in virus replication.
    Takahashi K; Sato Y; Sekizuka T; Kuroda M; Suzuki T; Hasegawa H; Katano H
    PLoS Pathog; 2020 Apr; 16(4):e1008523. PubMed ID: 32324824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients.
    Agostini S; Mancuso R; Costa AS; Caputo D; Clerici M
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33809082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
    Rossi F; Prosperini L; De Rossi N; Capra R; Rivanera D; Li X; Cinque P; Passeri L; Pozzilli C; Viscidi R
    Viral Immunol; 2017 Oct; 30(8):622-626. PubMed ID: 28836899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human JC polyomavirus (JCPyV): virological background and clinical implications.
    Hirsch HH; Kardas P; Kranz D; Leboeuf C
    APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
    Diotti RA; Capra R; Moiola L; Caputo V; De Rossi N; Sangalli F; Martinelli V; Burioni R; Clementi M; Mancini N
    Viruses; 2016 May; 8(5):. PubMed ID: 27164128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
    Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
    Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
    Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
    J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JC polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigen-sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Toyoda M; Thomas D; Ahn G; Kahwaji J; Mirocha J; Chu M; Vo A; Suviolahti E; Ge S; Jordan SC
    Transpl Infect Dis; 2015 Dec; 17(6):838-47. PubMed ID: 26437369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human iPS cell-derived astrocytes support efficient replication of progressive multifocal leukoencephalopathy-type JC polyomavirus.
    Shimbo E; Nukuzuma S; Tagawa YI
    Biochem Biophys Res Commun; 2020 Dec; 533(4):983-987. PubMed ID: 33008586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.
    Blankenbach K; Schwab N; Hofner B; Adams O; Keller-Stanislawski B; Warnke C
    Neurology; 2019 May; 92(19):e2232-e2239. PubMed ID: 30952796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding polyomavirus CNS disease - a perspective from mouse models.
    Ayers KN; Carey SN; Lukacher AE
    FEBS J; 2022 Oct; 289(19):5744-5761. PubMed ID: 34145975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
    Schneider-Hohendorf T; Schulte-Mecklenbeck A; Ostkamp P; Janoschka C; Pawlitzki M; Luessi F; Zipp F; Meuth SG; Klotz L; Wiendl H; Gross CC; Schwab N
    Mult Scler; 2021 Sep; 27(10):1491-1496. PubMed ID: 33150829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.